Page last updated: 2024-12-04

allysine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

L-allysine : An optically active form of allysine having L-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160603
CHEBI ID17917
SCHEMBL ID198242
MeSH IDM0040067

Synonyms (32)

Synonym
(2s)-2-amino-6-oxohexanoic acid
2-amino-5-formylvaleric acid
l-6-oxonorleucine
2-amino-6-oxo-hexanoic acid
CHEBI:17917
alpha-aminoadipic acid delta-semialdehyde
6-oxo-l-norleucine
l-2-aminoadipate 6-semialdehyde
l-allysine
C04076
ALLYSINE ,
2-aminoadipate semialdehyde
DB02571
6-oxo-norleucine
AKOS006284290
alpha-aminoadipic semialdehyde
norvaline, 5-formyl-
6665-12-9
425I4Y24YZ ,
.alpha.-aminoadipic acid delta.-semialdehyde
allysine [who-dd]
SCHEMBL198242
unii-425i4y24yz
AC-22380
(2s)-2-amino-6-oxohexanoate
5-formyl-norvaline
2-amino-5-formylvalerate
2-amino-hexanedioate
2-amino-hexanedioic acid semialdhyde
Q28529674
(s)-2-amino-6-oxohexanoic acid
(s)-2-amino-6-oxohexanoicacid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" P6C forms a complex with pyridoxal phosphate (PLP), a key vitamer of pyridoxine, thereby reducing PLP bioavailability and subsequently causing epilepsy."( Inherited Disorders of Lysine Metabolism: A Review.
Bouchereau, J; Schiff, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
aminoadipate semialdehyde
allysineAn alpha-amino acid consisting of lysine having an oxo group in place of the side-chain amino group.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Lysine degradation ( Lysine degradation )2029
NAD+ + L-Saccharopine + H2O = NADH + L-2-Amino-adipate 6-semialdehyde + L-Glutamic acid ( Lysine degradation )16
NAD+ + L-2-Amino-adipate 6-semialdehyde + H2O = NADH + L-2-Amino-adipic acid ( Lysine degradation )15
Metabolic Epileptic Disorders2589
lysine biosynthesis IV420
Biochemical pathways: part I0466

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (10.14)18.7374
1990's7 (10.14)18.2507
2000's14 (20.29)29.6817
2010's34 (49.28)24.3611
2020's7 (10.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.90%)5.53%
Reviews5 (7.25%)6.00%
Case Studies5 (7.25%)4.05%
Observational0 (0.00%)0.25%
Other57 (82.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]